Results 141 to 150 of about 1,869 (168)

Lebrikizumab in the treatment of asthma

Expert Opinion on Biological Therapy, 2016
Severe asthma continues to be a major clinical problem despite the availability of effective asthma medications such as inhaled corticosteroids. Several targeted biologic therapies are emerging to treat patients with severe asthma. Areas Covered: This review provides an update of information on lebrikizumab, a novel monoclonal antibody that targets IL ...
Stephen, Bujarski, Amit D, Parulekar, Nicola A, Hanania   +2 more
openaire   +2 more sources

Efficacy and Safety of Lebrikizumab in Adult Patients With Mild-to-Moderate Asthma Not Receiving Inhaled Corticosteroids [PDF]

Respiratory Medicine, 2018
Background: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma.
Philip Korenblat, Igor Leshchenko, Cecile T J Holweg   +2 more
exaly   +1 more source

Lebrikizumab

pharma-kritik
Lebrikizumab: Ein Interleukin-13-Hemmer. ebenfalls mit der Indikation einer schwierig behandelbaren atopischen Dermatitis.  Er ist dabei ähnlich wirksam wie andere systemisch verabreichte Wirkstoffe. Wie unter Dupilumab tritt auch unter diesem IL-Hemmer häufig eine Konjunktivitis auf.   
openaire   +1 more source

Lebrikizumab (Ebglyss) for Atopic Dermatitis

The Medical Letter on Drugs and Therapeutics
The FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg).
openaire   +2 more sources

Lebrikizumab-Lbkz for the Treatment of Atopic Dermatitis: A Drug Review

Annals of Pharmacotherapy
Background: Lebrikizumab is a monoclonal antibody targeting interleukin 13 (IL-13), a key cytokine in the pathogenesis of atopic dermatitis (AD). It was approved by the Food and Drug Administration (FDA) in 2024 for the treatment of moderate-to-severe AD in patients aged ≥12 years.
Steven R. Feldman
exaly   +3 more sources

Lebrikizumab

Drugs of the Future, 2014
null Pelaia, G., null Vatrella, A., null Gallelli, L., null Busceti, M., null Terracciano, R., null Maselli, R.   +5 more
openaire   +1 more source

Lebrikizumab bei atopischer Dermatitis

DMW - Deutsche Medizinische Wochenschrift, 2023
openaire   +1 more source

Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Skin therapy letter
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that impacts approximately 10-15% of the population in the United States and Canada. Lebrikizumab is a novel systemic human monoclonal immunoglobulin G4 antibody that inhibits the activity of interleukin-13.
Leah, Johnston, Susan, Poelman, Andrei, Metelitsa   +2 more
openaire   +1 more source

Lebrikizumab Monotherapy for the Treatment of Moderate to Severe Atopic Dermatitis

The Journal of Allergy and Clinical Immunology: In Practice, 2023
Nikki, Kimura, Punita, Ponda
openaire   +2 more sources

Lebrikizumab enttäuscht bei der IPF

Pneumologie, 2021
openaire   +1 more source